This is a YouTube script by a physician who is personally at high genetic risk for Alzheimer’s disease (carrying two copies of the APOE4 allele). He reviews a study published in Aging Biology that unexpectedly identified ezetimibe as a potential neuroprotective agent — not through its cholesterol-lowering mechanism, but through an entirely separate pathway in the brain.
Non-Cholesterol Benefits of Ezetimibe Discussed
The Core Mechanism
A hypothesis-neutral screen of FDA-approved drugs sought compounds that could disrupt the 14-3-3/hexokinase protein interaction — an early step in the cascade leading to protein misfolding in Alzheimer’s and other neurodegenerative diseases. Six drugs emerged from the screen; ezetimibe was the only cholesterol-lowering drug among them.
Key Findings from the Study
Reduced amyloid accumulation — ezetimibe significantly decreased amyloid buildup in human cell lines
Reduced tau accumulation — it markedly reduced tau protein, responsible for neurofibrillary tangles in Alzheimer’s
Boosted autophagy by ~40% — enhancing the brain’s cellular “cleanup system,” analogous to the effects of fasting
Animal model confirmation — amyloid reduction was replicated in C. elegans worm models
Human epidemiological data — in a retrospective analysis comparing 4,361 ezetimibe users to 945,000 age-matched controls, Alzheimer’s disease incidence was 8-fold lower in the ezetimibe group, independent of coronary disease status
Why Ezetimibe Specifically
Compared to the other five compounds identified in the screen, ezetimibe was favored because it:
Crosses the blood-brain barrier
Has an excellent and well-established safety profile (not associated with insulin resistance, diabetes, liver injury, or muscle damage, unlike statins)
Important Caveats the Author Acknowledges
The script is intellectually honest about limitations. There is no randomized controlled trial in humans, and the data come from in vitro cell lines, animal models, and a retrospective database analysis — all subject to confounding. The author stops well short of claiming ezetimibe prevents Alzheimer’s, while arguing the effect sizes are too large to dismiss and the mechanistic story is biologically coherent.
Desoxyn has high ratings on Drugs.com. This must mean that it’s safer than ezetimibe.
Let’s not forget that this is methamphetamine hydrochloride.
Anyway now we know the power of the placebo and nocebo effect, at least for Ezetimibe. There’s barely any side effect difference from placebo in clinical trials.
SGTL2 inhibitors can increase risk of UTI and yeast infection of genitals due to increase sugar output in urine. Main solution there is to make sure the area is clean.
Ezetimibe I take personally (10mg/d, have taken for years) and have zero discernible side effects. It’s highly effective in the job it’s supposed to do, which is lowering my LDL-C.
Empagliflozin I don’t take, but my friend is a pharmacist and he says the most common complaint from patients is UTIs - most commonly in women with obesity.
It also makes sense to increase fluid intake somewhat so that you dilute the urine and flush the kidneys. No need to go overboard, but timing can be useful. Personally, first thing in the morning I drink 500 ml of a green tea based drink (3-4g taurine + 2-3g TMG + 12g partially hydrolyzed guar gum + cranberry powder + blueberry powder + passion fruit powder). After you wake up, your urine is usually pretty concentrated, it makes sense to drink in the morning.
I have genetically high cholesterol that I manage through a whole food plant based diet and exercise program plus ezetimibe and low-dose atorvastatin. I wasn’t aware there may be longevity benefits to ezetimibe, happy to see this may be the case! I’ve taken 10 mgs ezetimibe for some time with zero side effects that I’m aware of, and it keeps my Apo(b) and LDL where my cardiologist and I want them. Hope this helps!
Thanks for this reminder about potential benefits of Ezetimibe! I added 10mg Ezetimibe in March '26 to my stack (I’m an ApoE4 with elevated amyloid plaque & p-tau 217). I check my blood markers every 6 months or so for my N=1 trials. Comparing various labs for tracking AD biomarkers but Precivity AD is my earliest and most consistently used labs. I will be taking my 4th Precivity AD biomarker test in July/August (first one was in 2022). I will see if Ezetimbe lowers my numbers. Fingers crossed!
I think they are very similar and your choice will be what works best for you. I tried canagliflozin but for some reason felt a lot of fatigue on it, switched to empagliflozin and no issues, so I’ve stayed with empagliflozin.
What are your thoughts on dapagliflozin and its longevity promoting properties compared to empagliflozin? I ran it through chat-gpt and they seem similar as far as i can tell.
Canagliflozin is the only “flozin” that has been tested in rigorous mammalian lifespan tests (the NIA’s ITP program)… so that is the only compound (I believe, unless I missed a study) that we have good data on. See: Canagliflozin - Another Top Longevity Drug
So - when we look at the other “flozin” compounds we really don’t know. If canagliflozin works for you, I’d use it because it’s the best characterized… it’s the one we know most about. The others “should” work, but we can’t be sure. We can be sure (at least in rodents) that canaglifozin increases lifespan.
Yes thank you, this is a safe medical answer that a Dr might share. I did review the studies on conaglifloznen. Just curious on your own personal opinions if you’re open to sharing them. I will of course do my own research and make my choices freely.
I think @RapAdmin did share his opinion above which is to say that most likely all “flozins” have the same effect as Cana, but CANA is the one measured/studied and it showed positive effects on lifespan. I doubt him (or anyone else for that matter) could offer any more than that in a rational way. Personally, I’m doing EMPA but do have a big supply of CANA also and intend to use it when my EMPA runs out. So, I’m agnostic as to which should I use. Initially ( I think) I started with EMPA because somewhere on these boards people were saying it may have less side effects. Other than that I would have gone with what was tested/studied, CANA.
Also, lactoferrin might help. According to lactoferrin.co, " Lactoferrin may assist in maintaining a healthy urinary environment. Lactoferrin is an immunity protein that suffocates infection causing bacteria in your bladder."
I’ve used a CGM (continuous blood glucose monitor) and tracked my blood glucose levels on both canagliflozin and empagliflozin. In both cases they seem to do a great job at flattening the post prandial (after a meal) blood glucose level. So from that standpoint they seem very similar (in my experience).
Thanks, I decided to give dapagliflozin a try. I seen some comments about people tolerating it a bit better and it was also cheaper from my source by almost 50% compared to empagliflozin. With a lot of these things we’re clearly taking a bit of a leap of faith hoping for benefits beyond their intended functions. I was just reading the thread about dasatinib and quercetin potentially having negative effects on the brain… Will have to take a closer look at those studies because I have used synolytics periodically like this that stack and FOXO4-DRI.
Personally, I have ordered Empaone Empagliflozin 10 mg tablets from India. This brand is dirt cheap (~$30 for 200 tablets) and has a good reputation for quality. Previously I ordered Jardiance from India, but was still not cheap.
MSN Laboratories has grown quickly since its founding in 2003, evolving from a small team into a significant player in the global generics market. While known for its manufacturing and R&D capabilities, the company’s public reputation is also colored by an aggressive strategy that has led to multiple legal challenges.
Here is a breakdown of the company’s size and standing:
Company Size & Scale
Workforce: MSN has expanded to over 20,000 employees worldwide, with more than 2,000 scientists working at one of Asia’s largest integrated R&D centers.
Revenue: MSN Laboratories’ revenue was $1 billion USD in the 2024-25 fiscal year, and the group’s overall revenue has reached ₹10,000 crore (approximately $1.2 billion).
Manufacturing Network: The company operates 25 manufacturing facilities, including 17 for Active Pharmaceutical Ingredients (APIs) and 8 for finished dosages, across India, the USA, Indonesia, and the UAE.
Global Reach: MSN has a commercial presence in over 100 countries.
Product & Pipeline
Portfolio: MSN manufactures over 500 APIs and 400 finished dosages covering more than 35 major therapeutic areas.
R&D: The company is known for its regulatory filings, holding the number one position globally for active US Drug Master Files (DMFs), having filed over 1,200 to date.
Reputation: Compliance, Innovation, and Legal Battles
MSN’s public reputation is defined by a duality: a proven commitment to manufacturing quality and an aggressive legal strategy that often results in patent infringement lawsuits.
A Commitment to Quality and Compliance
On one hand, MSN has built a solid reputation as a reliable manufacturer. Its facilities and processes hold approvals from stringent global regulators, including the USFDA, EU GMP, WHO, PMDA Japan, and Health Canada. A notable recent achievement was clearing a USFDA Postmarketing Adverse Drug Experience (PADE) inspection with zero observations, demonstrating a strong commitment to patient safety and pharmacovigilance compliance.
Company Size & Scale
Product & Pipeline
Reputation: Compliance, Innovation, and Legal Battles